However, systematic administration of rhEPO in xenograft mice to address tumorigenic effect of endogenous EPO is inappropriate because that may confound its pro-tumor effects by other affected organs and systems such as hematopoietic and immune systems. The gene discussed is EPO; the disease is neoplasm.